Substituted heterocyclic compounds and uses thereof

Details Substituted heterocyclic compounds and uses thereof Substituted heterocyclic compounds and uses thereof

2005-09-01

2008-12-23

Sullivan, Daniel M (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S520000, C514S576000, C558S402000

Reexamination Certificate

active

07468446

ABSTRACT:
The present invention relates to substituted heterocyclic compounds and compositions comprising a substituted heterocyclic compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof one or more substituted heterocyclic compounds. In particular, the invention relates to methods for preventing or treating cancer or an inflammatory disorder by administering to a subject in need thereof one or more substituted heterocyclic compounds. The present invention further relates to articles of manufacture and kits comprising one or more substituted heterocyclic compounds.

REFERENCES:
patent: 3094533 (1963-06-01), Hughes
patent: 4492708 (1985-01-01), Spitzer
patent: 5006435 (1991-04-01), Akasaki et al.
patent: 5414008 (1995-05-01), Muller et al.
patent: 5929117 (1999-07-01), Muller et al.
patent: 6130226 (2000-10-01), Muller et al.
patent: 6262101 (2001-07-01), Muller et al.
patent: 6667316 (2003-12-01), Man et al.
patent: 7019030 (2006-03-01), Muller et al.
patent: 2001/0056107 (2001-12-01), Muller et al.
patent: EP 0 208 999 (1987-01-01), None
patent: 0 091 795 (1983-10-01), None
patent: 0 316 594 (1989-05-01), None
patent: 0 665 224 (1995-08-01), None
patent: 58-188868 (1983-11-01), None
patent: 63 239274 (1988-10-01), None
patent: 5-66591 (1993-03-01), None
patent: WO 96/20926 (1996-07-01), None
patent: WO 96/21435 (1996-07-01), None
patent: WO 97/08143 (1997-03-01), None
patent: WO 97/23457 (1997-07-01), None
patent: WO 98/06692 (1998-02-01), None
patent: WO 00/01387 (2000-01-01), None
patent: WO 02/24658 (2002-03-01), None
patent: WO 2004/060313 (2004-07-01), None
Bedford et al., 1996, “Synthesis of water-soluble prodrugs of the cytotoxic agent combretastatin A4”, Bioorganic & Medicinal Chemistry Lett 6(2):157-160.
Chen et al., 2000, “Preparation of new anti-tubulin ligands through a dual-mode, addition-elimination reaction to a bromo-substituted α, β-unsaturated sulfoxide”, J Org. Chem 65:8811-8815.
Cummins et al., 1971, “Preparation, properties, and structure of some organotin acrylates”, Aust J Chem 24(11):2257-2266.
Cushman et al., 1993, “Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents”, J Med Chem 35(12):2293-2306.
Danion et al., 1972, Tetrahedron 28(15):4223-4229 (w/ English language abstract).
Fischer et al., 1993, J Organomet Chem 54(1-2):133-149 (w/ English language abstract).
Groundwater et al., 1992, “Electrocyclic aromatic substitution by nitrile Ylides to Give 3H-2-benzazepines: substituent effects and mechanism”, Tetrahedron 48(37):7951-7964.
Gwaltney et al., 2001, “Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents”, Bioorg Med Chem Lett 11(7):871-874.
Hamel E, 1996, “Antimitotic natural products and their interactions with tubulin”, Med Res Rev 16(2):207-231.
Hastie SB, 1991, “Interactions of colchicine with tubulin”, Pharmacol Ther 51(3):377-401.
Ilg et al., 2001, “Substitution and migratory insertion reactions of square-planar allenyliden iridium complexes”, Organometallics 20(17):3782-3794.
Laubender et al., 1998, “Unprecedented C-N coupling following migration of an azido ligand to a C=C=CRR′ unit”, Angewandte Chemie Int Ed 37(1/2):150-152.
Laubender et al., 1999, “Azide migration and azide bridging: preparation of metalated acrylonitriless and of dinuclear complexes containing an almost linear eleven-membered C3RhN3RhC3chain”, Chem Eur J 5(10):2937-2946.
Li et al., 2002, “Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent”, Bioorg Med Chem Lett 12(3):465-469.
Liou et al., 2002, “Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents”, J Med Chem 45(12):2556-2562.
Luduena et al., 1991, “Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents”, Pharmacol Ther 49(1-2):133-152.
McGown et al., 1990, “Differential cytotoxicity of combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines”, Cancer Chemother Pharmacol 26(1):79-81.
Medarde et al., 1999, “Synthesis and pharmacological activity of diarylindole derivatives. Cytotoxic agents based on combretastatins”, Bioorg Med Chem Lett 9(16):2303-2308.
Mu et al., 2001, “Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin polymerization”, J Med Chem 44(3):441-452.
Nam et al., 2002, “Synthesis and anti-tumor activity of novel combretastatins: combretocyclopentenones and related analogues”, Bioorg Med Chem Lett 12(15):1955-1958.
Ohsumi et al., 1998, “Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships”, J Med Chem 41(16):3022-3032.
Ohsumi et al., 1998, “Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues”, Bioorg Med Chem Lett 8(22):3153-3158.
Pac et al., 1984, “Redox-photosensitized reactions. 11. Fu(bpy)32+-Photosensitized reactions of 1-benzyl-1,4-dihydronicontinamide with aryl-substituted enones, derivatives of methyl cinnamate, and substituted cinnamonitriles: electron-transfer mechanism and structure-reactivity relationships”, J Org Chem 49(1):26-34.
Pettit et al., 1989, “Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4”, Experientia. 45(2):209-211.
Pettit et al., 1998, “Antineoplastic agents. 379. Synthesis of phenstatin phosphate”, J Med Chem 41(10):1688-1695.
Pettit et al., 1999, “Antineoplastic agents. 410. Asymmetric hydroxylation of trans-combretastatin A-4”, J Med Chem 42(8):1459-1465.
Pettit et al., 2000, “Antineoplastic agents. 443. Synthesis of the cancer cell growth inhibitor hydroxyphenstatin and its sodium diphosphate prodrug”, J Med Chem 43(14):2731-2737.
Pettit et al., 2002, “Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate”, J Med Chem 45(12):2534-2542.
Profitt et al., 1975, “A Reagent for the α, β Reduction of Conjugated Nitriles”, J Org Chem 40(1): 127-128.
Shirai et al., 1998, “Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells”, Bioorg Med Chem Lett 8(15):1997-2000.
Thorpe PE, 2004, “Vascular targeting agents as cancer therapeutics”, Clin Cancer Res 10(2):415-427.
“Update on Spindle Poisons, Part II: Vinca Alkaloids and Analogs/Formulations”, 2002, Future Oncology 6(12):1457-1484.
“Update on Spindle Poisons—Part III: Novel Agents in Development”, 2002, Future Oncology 7(1/2):1485-1528.
Verdier-Pinard et al., 1998, “Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells”, Mol Pharmacol 53(1):62-76.
Wang et al., 2002, “Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation”, J Med Chem 45(8):1697-1711.
Yoon et al., 2002, “CP248, a derivative of exisulind, causes growth inhibition, mitotic arrest, and abnormalities in microtubule polymerization in glioma cells”, Mol Cancer Ther 1(6):393-404.
Campaigne et al., 1970, “Novel amination reactions of dihydrofurano [2,3-d] pyrimidines (1),” J. Heterocyclic Chem. 7(1):43-9.
Zhou et al., 2003, “An

Affiliated with

Also associated with

Rating

Substituted heterocyclic compounds and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted heterocyclic compounds and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted heterocyclic compounds and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4051560